PCK1 and SLC22A2 gene variants associated with response to metformin treatment in type 2 diabetes.

doi:10.1371/journal.pone.0305511

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

PCK1 and SLC22A2 gene variants associated with response to metformin treatment in type 2 diabetes.

PloS one - 1 Jan 2025

St-Amour Sophie, Tessier Laurence, Harnois Janie, Allard Catherine, Lavoie Alexandre, Caron Philippe, Bouchard Luigi, Perron Patrice, Tremblay Karine

Abstract excerpt

Type 2 diabetes (T2D) is a chronic disorder affecting 462 million worldwide, often managed with metformin as first-line treatment. However, metformin's response varies among individuals, including up to 30% experiencing serious adverse drug reactions (ADRs) and 20-50% inefficacy. These differences may be due to various factors, including pharmacogenetic (PGx) variants. The PGx variants documented so far could...

Read the complete abstract on PubMed

Topics

Humans
Metformin
Diabetes Mellitus, Type 2
Female
Male
Middle Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Hypoglycemic Agents

Organic Cation Transporter 2

Polymorphism, Single Nucleotide

Intracellular Signaling Peptides and Proteins

Aged

Genotype

Phosphoenolpyruvate Carboxykinase (GTP)

Source

Open in PubMed Open full text

Identifiers

PMID: 39928707
DOI: 10.1371/journal.pone.0305511
PMCID: PMC11809887

Genes

PCK1
SLC22A2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PCK1 and SLC22A2 gene variants associated with response to metformin treatment in type 2 diabetes.PMID 39928707Read ↗

Implications of genetic variations, differential gene expression, and allele-specific expression on metformin response in drug-naïve type 2 diabetes.Semantic proximity Read ↗

A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 DiabetesSemantic proximity Read ↗

Metformin Pharmacogenomics: Current Status and Future DirectionsSemantic proximity Read ↗

An Update on the Pharmacogenomics of Metformin: Progress, Problems and PotentialSemantic proximity Read ↗

Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.Semantic proximity Read ↗

Influence of GLUT2 rs8192675, MATE1 rs2289669, and OCT2 rs316019 Genetic Polymorphism on Metformin Efficacy and Glycemic Control in Type 2 Diabetes Mellitus PatientsSemantic proximity Read ↗

Pharmacogenetics of Oral Antidiabetic DrugsSemantic proximity Read ↗

Pharmacogenetic impact of SLC22A1 gene variant rs628031 (G/A) in newly diagnosed Indian type 2 diabetes patients undergoing metformin monotherapy.Semantic proximity Read ↗

The influence of SLC22A3 rs543159 and rs1317652 genetic variants on metformin therapeutic efficacy in newly diagnosed patients with type 2 diabetes mellitus: 25 weeks follow-up study.Semantic proximity Read ↗

The pharmacogenetics of metformin.Semantic proximity Read ↗

Effects of genetic variants of organic cation transporters on metformin response in newly diagnosed patients with type 2 diabetes.Semantic proximity Read ↗

Evaluation of PRKAA2 Genetic Variation on Metformin Efficacy as an Initial Therapy Among Drug-Naïve Patients With Type II Diabetes MellitusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.